Skip to main content
Fig. 5 | Molecular Autism

Fig. 5

From: High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons

Fig. 5

HDAC inhibitors lower the mRNA and the protein levels of GTF2I in 7Dup iNs. a Relative expression of BAZ1B, CLIP2, EIF4H, and GTF2I mRNA (mean ± SD) in WBS01CN3 and Dup02K iNs (n = 2) treated with Domatinostat 10 μM compared to control (DMSO). Error bars represent variation between lines of the two genotypes (Holm-Sidak-corrected t test ***P < 0.001). b Relative expression of GTF2I mRNA (mean ± SD) in two 7Dup-derived iNs, Dup02K and Dup01G, treated with different classes of epigenetic compounds compared to control. Error bars represent variation between the two above-mentioned iN lines (one way ANOVA test: *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001). Relative expression of GTF2I mRNA (mean ± SE) in Dup03B (c), Dup04A (e), Dup01G (g) and Dup02K (i) iNs treated with vorinostat 10 μM, mocetinostat 10 μM and RG2833 10 μM compared to control. Relative expression was measured by RT-qPCR, normalized against GAPDH-SRSF9-RPS18 geometric mean. In c, e, g, i error bars represent variation between three technical replicates. Protein levels of GTF2I in Dup03B (d), Dup04A (f) and Dup01G (h) iNs treated with vorinostat, mocetinostat and RG2833 10 μM each compared to control. Immunoblot (left) and densitometric analysis (right). j Protein levels of GTF2I in Dup04A iNs treated with different concentrations of vorinostat (0,1-1-10 μM) compared to control. Immunoblot (left) and densitometric analysis (right)

Back to article page

Molecular Autism

ISSN: 2040-2392